stage,date_text,end_date,ticker,price,drug
Phase 1/2,January 12-17 ,01/12/2018,BPMX,0.12,BPX-04
Phase 2,Mid-late January 2018 ,01/16/2018,EIGR,16.00,Ubenimex - LIBERTY
Phase 2,,01/19/2018,BLRX,1.16,BL-8040 in combination with KEYTRUDA - COMBAT trial
Phase 3,,01/19/2018,EXEL,30.38,XL184 cabozantinib (CELESTIAL)
Phase 2,,01/19/2018,TCON,2.90,TRC105 and Nexavar
PDUFA,,01/24/2018,SGYP,2.39,Trulance (plecanatide)
PDUFA,,01/26/2018,AAAP,81.84,Lutathera
PDUFA priority review,,01/26/2018,ARDM,2.26,Linhaliq (Pulmaquin)
Phase 2,January 2018 ,01/31/2018,KDMN,4.23,KD025
Phase 3,January 2018 ,01/31/2018,PHMMF,3.19,Zepsyre(PM1183)
PDUFA,,02/02/2018,AMAG,14.40,Feraheme
Phase 1/2,"February 8-10, 2018 ",02/08/2018,AVEO,3.10,Tivozanib + Opdivo
Phase 2,,02/10/2018,TCON,2.90,DE-122 and Lucentis - AVANTE
PDUFA priority review,,02/12/2018,GILD,79.02,Bictegravir/F/TAF
PDUFA,,02/13/2018,VRX,23.84,Plenvu (NER1006)
PDUFA,,02/14/2018,AMAG,14.40,Makena - auto injector
PDUFA,,02/14/2018,ATRS,2.28,Makena - auto injector
PDUFA,Adcom 2/14/18; PDUFA 4/6/18 ,02/14/2018,PCRX,41.50,EXPAREL
Phase 2,"February 15-17, 2018 ",02/15/2018,KURA,16.05,Tipifarnib
PDUFA,,02/17/2018,APRI,2.74,Vitaros
Phase 2,,02/17/2018,IMNP,0.60,Bertilimumab
PDUFA,,02/23/2018,KMPH,5.00,KP201/APAP
Phase 3,February 2018 ,02/28/2018,AIMT,39.43,AR101 PALISADE
Phase 1/2,February 2018 ,02/28/2018,AST,2.45,AST-OPC1 SCiSTAR
Phase 3,Early 2018 ,02/28/2018,CRMD,0.53,Neutrolin - LOCK-IT 100
Phase 2,Early 2018 ,02/28/2018,MDGL,107.00,MGL-3196
Phase 2,Early 2018 ,02/28/2018,MRNS,7.34,Ganaxolone
Phase 1/2,Feb 2018 ,02/28/2018,NVAX,1.61,NanoFlu vaccine
Phase 3,Late 2017/early 2018 ,02/28/2018,ONTX,1.83,IV Rigosertib - INSPIRE
Phase 1/2,Early 2018 ,02/28/2018,RXII,4.29,RXI-109-1501
PDUFA,,02/28/2018,SRNE,4.95,ZTlido (lidocaine patch 1.8%)
Phase 1,February 2018 ,02/28/2018,SRRA,3.25,SRA737
PDUFA priority review,,02/28/2018,VRTX,157.93,Tezacaftor (VX-661) / ivacaftor
PDUFA,,03/02/2018,OTIC,5.85,OTIPRIO
PDUFA,,03/05/2018,BMY,62.81,Opdivo -  4 week applications
Phase 2b,Early-2018 ,03/30/2018,BIIB,335.95,Natalizumab (α4-integrin inhibitor)
Phase 2b,March 2018 ,03/31/2018,ABIO,1.65,Gencaro - GENETIC-AF trial
Phase 3,1Q 2018 ,03/31/2018,ACOR,25.85,Tozadenant
Phase 1/2,1Q 2018 ,03/31/2018,ALT,1.96,NasoVAX
Phase 2a,1Q 2018 ,03/31/2018,ANAB,112.40,ANB020
Phase 3,1Q 2018 ,03/31/2018,ANTH,1.35,Sollpura - RESULT
Phase 2,1Q or 2Q 2018 ,03/31/2018,ARNA,34.95,APD371
Phase 2,1Q 2018 ,03/31/2018,ARNA,34.95,Etrasimod
Phase 3,1Q 2018 ,03/31/2018,BHVN,26.44,Rimegepant
Phase 2,Early 2018 ,03/31/2018,BPTH,0.23,Prexigebersen
Phase 1/2,Early 2018 ,03/31/2018,CBIO,15.13,CB 2679d/ ISU304
Phase 2,1Q 2018 ,03/31/2018,CDTX,7.55,Rezafungin (CD101) IV - STRIVE
Phase 3,1Q 2018 ,03/31/2018,CELG,106.00,REVLIMID - AUGMENT NHL-007
Phase 2,1Q 2018 ,03/31/2018,CELG,106.00,OTEZLA
Phase 2,1Q 2018 ,03/31/2018,CLBS,4.08,CLBS03
Phase 3,1Q 2018 ,03/31/2018,CLSD,6.35,Suprachoroidal CLS-TA - PEACHTREE
Phase 2,1Q 2018 ,03/31/2018,CORT,20.65,CORT125134
Phase 2,1Q 2018 ,03/31/2018,CYTK,8.85,CK-2127107
Phase 3,1Q 2018 ,03/31/2018,DERM,27.44,Olumacostat glasaretil (DRM01)
Phase 3,1Q 2018 - likely February ,03/31/2018,EARS,0.48,Keyzilen (AM-101) - TACTT3
Phase 3,1Q 2018 ,03/31/2018,EDGE,10.77,EG-1962
Phase 2,1Q 2018 ,03/31/2018,ESPR,73.26,Bempedoic Acid - 1002-039
Phase 3,"March, May and September 2018 ",03/31/2018,ESPR,73.26,"Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048"
Phase 2b,1Q 2018. ,03/31/2018,EYEG,1.26,EGP-437
Phase 2,1Q 2018 ,03/31/2018,FGEN,49.50,Pamrevlumab (FG-3019)
Phase 2,1Q 2018 ,03/31/2018,FLKS,4.20,FLX-787 (Aust)
Phase 2b,1Q 2018 ,03/31/2018,GALE,0.26,NeuVax in combination with Herceptin
Phase 2,1Q 2018 ,03/31/2018,GERN,2.04,Imetelstat - IMbarkStudy
Phase 2,1Q 2018 ,03/31/2018,GILD,79.02,GS-9674
Phase 3,1Q 2018 ,03/31/2018,GILD,79.02,GS-5745
Phase 2,1Q 2018 ,03/31/2018,GILD,79.02,GS-9674
Phase 2,1Q 2018 ,03/31/2018,GILD,79.02,Entospletinib
Phase 2,1Q 2018 ,03/31/2018,GLMD,11.07,Aramchol - ARRIVE
Phase 3,1Q 2018 ,03/31/2018,GSK,37.50,Dolutegravir + lamivudine (GEMINI 2)
Phase 3,1Q 2018 ,03/31/2018,GSK,37.50,Dolutegravir + lamivudine (GEMINI 1)
Phase 2,1Q 2018 ,03/31/2018,GTHX,23.04,Trilaciclib
Phase 3,1Q 2018 ,03/31/2018,GWPH,131.97,Epidiolex
Phase 2,1Q 2018 ,03/31/2018,GWPH,131.97,GWP42006 (CBDV)
Phase 2,1Q 2018 ,03/31/2018,IMRN,7.45,IMM-124E
Phase 1,Early 2018 ,03/31/2018,MBIO,11.77,MB-102
Phase 1,Early 2018 ,03/31/2018,MBIO,11.77,MB-101
Phase 1/2,1Q 2018 ,03/31/2018,MBVX,0.90,MVT-5873
Phase 1b,Early 2018 ,03/31/2018,MCRB,10.52,SER-262
Phase 2b,1Q 2018 ,03/31/2018,MESO,5.89,MPC-150-IM - Class IV
Phase 3,1Q 2018 ,03/31/2018,MESO,5.89,MSC-100-IV
Phase 3,1Q 2018 ,03/31/2018,MRK,58.66,(MK-3475-189/KEYNOTE-189)
Phase 2,1Q 2018 ,03/31/2018,MRTX,24.75,Mocetinostat and durvalumab
Phase 2,1Q 2018 ,03/31/2018,MYOK,52.90,MYK-461 - PIONEER-HCM
Phase 3,1Q 2018 ,03/31/2018,NBIX,81.37,Elagolix
Phase 3,1Q 2018 ,03/31/2018,NVO,55.04,Semaglutide - oral - PIONEER
Phase 2,1Q 2018 ,03/31/2018,OBSV,9.70,OBE001 - IMPLANT2
Phase 2,1Q 2018 ,03/31/2018,PLX,0.74,OPRX-106
Phase 2b,Early 2018 ,03/31/2018,PTGX,19.84,PTG-100
Phase 1,1Q 2018 ,03/31/2018,PTI,5.04,PTI-428 + Kalydeco
Phase 2,1Q 2018 ,03/31/2018,REGN,366.96,Cemiplimab
Phase 3,1Q 2018 ,03/31/2018,REGN,366.96,Praluent (alirocumab) ODYSSEY OUTCOMES
Phase 2,1Q 2018 ,03/31/2018,RETA,28.43,Bardoxolone methyl - LARIAT
Phase 2,1Q 2018 ,03/31/2018,RETA,28.43,Omaveloxolone - MOTOR
Phase 1/2,1Q 2018 ,03/31/2018,RGLS,1.23,RG-012
Phase 2a,1Q 2018 ,03/31/2018,RNN,2.12,RX-3117
Phase 2,1Q 2018 ,03/31/2018,RNN,2.12,RX-3117
Phase 2a,1Q 2018 ,03/31/2018,RNN,2.12,Archexin
Phase 2,1Q 2018 ,03/31/2018,SMMT,12.68,Ezutromid
Phase 2,Late-1Q 2018 ,03/31/2018,SPHS,2.29,Topsalysin (PRX302)
Phase 3,1Q 2018 ,03/31/2018,SPPI,19.42,SPI-2012 (ROLONTIS)
Phase 3,1Q 2018 ,03/31/2018,TTPH,6.51,Eravacycline (TP-434) - IGNITE3
Phase 3,1Q 2018 ,03/31/2018,VBLT,8.30,VB-111
Phase 3,1Q 2018 ,03/31/2018,VICL,1.85,ASP0113 Vaccine
Phase 2,1Q 2018 ,03/31/2018,VNDA,14.50,HETLIOZ (tasimelteon)
Phase 1/2,Early 2018 ,03/31/2018,VTVT,5.54,TTP399
Phase 3,Early 2018 ,03/31/2018,VTVT,5.54,Azeliragon - STEADFAST
Phase 1b,1Q 2018 ,03/31/2018,VYGR,18.38,VY-AADC01
PDUFA priority review,,04/03/2018,MRK,58.66,Keytruda
PDUFA,,04/03/2018,THERF,6.29,Ibalizumab
PDUFA priority review,,04/06/2018,CLVS,59.01,Rucaparib ARIEL3
Phase 2,EASL 2018. ,04/11/2018,EIGR,16.00,Pegylated Interferon Lambda (LIMT HDV)
PDUFA priority review,,04/12/2018,LLY,86.98,Abemaciclib - MONARCH 3
PDUFA priority review,,04/16/2018,BMY,62.81,CM-214 – Opdivo + Yervoy
PDUFA priority review,,04/17/2018,RARE,47.80,KRN23 Burosumab
PDUFA,,04/17/2018,RIGL,4.07,Fostamatinib
PDUFA priority review,,04/27/2018,NBIX,81.37,Elagolix
PDUFA,,04/28/2018,SCMP,18.05,Lubiprostone
Phase 3,Fall 2018 ,04/30/2018,ALKS,58.71,ALKS 3831 - ENLIGHTEN-2
PDUFA,,04/30/2018,AMGN,185.04,KYPROLIS (ENDEAVOR)
Phase 2b,April 2018 ,04/30/2018,KPTI,10.78,Selinexor - STORM
Phase 3,Spring 2018 ,04/30/2018,NBRV,6.18,Lefamulin - LEAP 2
PDUFA priority review,,04/30/2018,PGNX,6.34,Azedra
PDUFA priority review,,05/01/2018,SGEN,52.36,ADCETRIS  in combination with chemotherapy ECHELON-1
PDUFA,,05/04/2018,PTLA,52.62,Andexanet alfa
PDUFA,,05/08/2018,LPCN,1.71,LPCN 1021
PDUFA priority review,Estimate mid-2Q 2018 ,05/15/2018,AZN,35.65,Tagrisso - FLAURA
PDUFA,,05/17/2018,AMGN,185.04,Erenumab
PDUFA,,05/17/2018,NVS,86.65,Erenumab
PDUFA priority review,,05/21/2018,DOVA,29.72,Avatrombopag
PDUFA priority review,,05/25/2018,BMRN,90.22,Pegvaliase
PDUFA,,05/26/2018,REPH,8.87,Intravenous (IV) meloxicam
PDUFA,,05/28/2018,AMGN,185.04,Prolia (denosumab)
PDUFA,,05/29/2018,TXMD,6.15,Yuvvexy - TX-004HR
Phase 3,May 2018 ,05/31/2018,ESPR,73.26,Bempedoic acid (ETC-1002-040) - Clear Harmony
PDUFA,,05/31/2018,KTOV,2.30,KIT-302
PDUFA priority review,Estimate mid-2Q 2018 ,05/31/2018,NVS,86.65,Tafinlar (dabrafenib) and Mekinist (trametinib)
Phase 2,ASCO 2018 ,06/01/2018,IDRA,2.49,IMO-2125 + ipilimumab - ILLUMINATE 204
PDUFA,,06/13/2018,PFE,36.54,Xeljanz
PDUFA,,06/18/2018,VRX,23.84,IDP-118
PDUFA priority review,,06/25/2018,AKAO,11.94,Plazomicin
PDUFA priority review,,06/27/2018,GWPH,131.97,Epidiolex
Phase 2,2Q 2018 ,06/30/2018,ABBV,100.34,Rova-T (TRINITY)
Phase 2,1H 2018 ,06/30/2018,ACRS,25.00,ATI-50002 - PK/safety
Phase 2,1H 2018 ,06/30/2018,ACRS,25.00,ATI-50002 - open label
Phase 2,1H 2018 ,06/30/2018,AGN,176.05,Brimo DDS
Phase 2b,1H 2018 ,06/30/2018,AGN,176.05,ATOGEPANT
Phase 3,1H 2018 ,06/30/2018,AGN,176.05,UBROGEPANT
PDUFA,1H 2018 ,06/30/2018,AGN,176.05,ESMYA  (ulipristal acetate)
Phase 2a,1H 2018 ,06/30/2018,ALRN,9.69,ALRN-6924
Phase 2a,2Q 2018 ,06/30/2018,ANAB,112.40,ANB020
Phase 3,1H 2018 ,06/30/2018,ANIK,56.64,Cingal
Phase 3,1H 2018 ,06/30/2018,ARGS,0.16,rocapuldencel-T (AGS-003) ADAPT Trial
Phase 1,1H 2018 ,06/30/2018,ARGS,0.16,AGS-004 and vorinostat
PDUFA,,06/30/2018,ARRY,13.71,Binimetinib - COLUMBUS
Phase 3,2Q 2018 ,06/30/2018,AVEO,3.10,TIVO-3 - tivozanib
Phase 2,2Q 2018 ,06/30/2018,AVIR,0.68,BTA074 5% topical gel
Phase 2,2Q 2018 ,06/30/2018,AXON,2.09,Nelotanserin
Phase 3,1H 2018 ,06/30/2018,AXSM,3.30,AXS-05 STRIDE-1
Phase 3,1H 2018 ,06/30/2018,AZN,35.65,Selumetinib - ASTRA
Phase 3,1H 2018 ,06/30/2018,AZN,35.65,PT010
Phase 3,1H 2018 ,06/30/2018,AZN,35.65,Lynparza
Phase 3,1H 2018 ,06/30/2018,AZN,35.65,Durvalumab +/- tremelimumab (MYSTIC)
Phase 3,1H 2018 ,06/30/2018,AZN,35.65,Durvalumab +/- tremelimumab (KESTREL)
Phase 3,1H 2018 ,06/30/2018,AZN,35.65,Durvalumab +/- tremelimumab (EAGLE)
Phase 3,1H 2018 ,06/30/2018,AZN,35.65,Durvalumab +/- tremelimumab (ARCTIC)
Phase 3,1H 2018 ,06/30/2018,BMY,62.81,CM-714 Opdivo + Yervoy
Phase 3,1H 2018 ,06/30/2018,BMY,62.81,CM-511 – Opdivo + Yervoy
Phase 3,1H 2018 ,06/30/2018,BMY,62.81,CM-331– Opdivo
Phase 3,1H 2018 ,06/30/2018,BMY,62.81,CM-227 – Opdivo + Yervoy
Phase 2,1H 2018 ,06/30/2018,BMY,62.81,CM-548 - Opdivo+SOC
Phase 1/2,2Q 2018 ,06/30/2018,BOLD,37.47,AT342 - VALENS
Phase 2,1H 2018 ,06/30/2018,CBIO,15.13,Marzeptacog alfa
Phase 1/2,1H 2018 ,06/30/2018,CKPT,3.70,CK-101
Phase 2b,2Q 2018 ,06/30/2018,CLDX,2.80,Glembatumumab vedotin
Phase 2,2Q 2018 ,06/30/2018,CLSD,6.35,Suprachoroidal CLS-TA - TYBEE
Phase 1/2,2Q 2018 ,06/30/2018,CLSD,6.35,Suprachoroidal CLS-TA - HULK
Phase 2b,1H 2018 ,06/30/2018,CNAT,4.69,Emricasan
Phase 1,1H 2018 ,06/30/2018,CORI,11.95,Corplex Donepezil
Phase 3,1H 2018 ,06/30/2018,CPRX,3.92,Firdapse
Phase 3,1H 2018 ,06/30/2018,CTIC,3.41,PIXUVRI - PIX306 Trial
Phase 2b,1H 2018 ,06/30/2018,DBVT,26.29,Viaskin Milk
PDUFA,,06/30/2018,DERM,27.44,Glycopyrronium tosylate (DRM04)
Phase 3,1H 2018 ,06/30/2018,EXEL,30.38,IMblaze370 - cobimetinib and atezolizumab
Phase 3,2Q 2018 ,06/30/2018,EYEG,1.26,EGP-437
Phase 2,1H 2018 ,06/30/2018,FBIO,4.14,CEVA101
Phase 2,1H 2018 ,06/30/2018,FBIO,4.14,Pepvax vaccine
Phase 3,2Q 2018 ,06/30/2018,FBIO,4.14,IV Tramadol
Phase 2b,2Q 2018 ,06/30/2018,GEMP,7.52,Gemcabene - INDIGO-1
Phase 2,2Q 2018 ,06/30/2018,GILD,79.02,Selonsertib (GS-4997)
Phase 2b,2Q 2018 ,06/30/2018,GLMD,11.07,Aramchol - ARREST
Phase 2,1H 2018 ,06/30/2018,GLPG,108.38,GLPG2737 - PELICAN
Phase 2,2Q 2018 ,06/30/2018,GLPG,108.38,Filgotinib - TORTUGA
Phase 2,2Q 2018 ,06/30/2018,GLPG,108.38,Filgotinib - EQUATOR
Phase 1b,2Q 2018 ,06/30/2018,GTHX,23.04,G1T38 plus Faslodex
Phase 3,1H 2018 ,06/30/2018,HRTX,21.40,HTX-011
Phase 2,2Q 2018 ,06/30/2018,IDRA,2.49,IMO-8400
Phase 1,1H 2018 ,06/30/2018,IMMP,1.90,Eftilagimod alpha and Keytruda
Phase 3,1H 2018 ,06/30/2018,INCY,94.07,Epacadostat with Keytruda - ECHO-301
Phase 3,1H 2018 ,06/30/2018,INCY,94.07,Ruxolitinib - REACH 1
Phase 1,2Q 2018 ,06/30/2018,INFI,2.05,IPI-549 + Nivolumab
Phase 1/2,1H 2018 ,06/30/2018,IONS,53.22,IONIS-HTT Rx
Phase 1/2,1H 2018 ,06/30/2018,JNCE,16.37,JTX-2011
Phase 3,2018 ,06/30/2018,JNJ,145.76,Esketamine
Phase 3,2Q 2018 ,06/30/2018,KMPH,5.00,KP415
Phase 2,1H 2018 ,06/30/2018,KURA,16.05,Tipifarnib
Phase 2,1H 2018 ,06/30/2018,MACK,10.74,MM-141 - CARRIE
Phase 3,1H 2018 ,06/30/2018,MDWD,4.60,NexoBrid
Phase 2,1H 2018 ,06/30/2018,MEIP,2.36,Pracinostat in combination with Vidaza
Phase 2,1H 2018 ,06/30/2018,MGNX,20.53,Margetuximab in combination with pembrolizumab
Phase 2,2Q 2018 ,06/30/2018,MTNB,1.27,MAT2501
Phase 2a,1H 2018 ,06/30/2018,NBIX,81.37,NBI-74788
Phase 2,1H 2018 ,06/30/2018,NLNK,8.58,Indoximod + gemcitabine and nab-paclitaxel
Phase 3,2Q 2018 ,06/30/2018,NVS,86.65,LEE011: MONALEESA-3
Phase 3,1H 2018 ,06/30/2018,PBYI,99.25,Neratinib
Phase 3,1H 2018 ,06/30/2018,PFNX,3.45,PF708 and Forteo
Phase 2b,2Q 2018 ,06/30/2018,PRTA,41.33,NEOD001 PRONTO
Phase 2,1H 2018 ,06/30/2018,PSTI,1.61,PLX-PAD (stem cells)
Phase 2a,2Q 2018 ,06/30/2018,RNN,2.12,Supinoxin
Phase 1b,1H 2018 ,06/30/2018,RXDX,26.95,RXDX-105
Phase 2,1Q/2Q 2018 ,06/30/2018,RXII,4.29,Samcyprone - RXI-SCP-1502
Phase 2,1H 2018 ,06/30/2018,RYTM,27.40,Setmelanotide
Phase 2,2Q 2018 ,06/30/2018,SAGE,175.86,SAGE-217
Phase 3,2Q 2018 ,06/30/2018,SBBP,8.00,COR-003 (levoketoconazole) - SONICS
Phase 1/2,1H 2018 ,06/30/2018,SGMO,18.30,SB-525 cDNA gene therapy
Phase 1/2,1H 2018 ,06/30/2018,SGMO,18.30,SB-318
Phase 1/2,1H 2018 ,06/30/2018,SGMO,18.30,SB-913 - CHAMPIONS
Phase 1/2,1H 2018 ,06/30/2018,SNDX,9.19,Entinostat plus Keytruda - ENCORE 601
Phase 3,1H 2018 ,06/30/2018,SNDX,9.19,E2112
Phase 3,1H 2018 ,06/30/2018,SNGX,2.22,SGX301 (synthetic hypericin)
Phase 2,1H 2018 ,06/30/2018,SVRA,13.05,Aironite - INDIE
Phase 2a,1H 2018 ,06/30/2018,TBPH,26.98,TD-9855
Phase 1/2,1H 2018 ,06/30/2018,TCON,2.90,TRC253
Phase 2,1H 2018 ,06/30/2018,TCON,2.90,TRC105 and Inlyta
Phase 3,2Q 2018 ,06/30/2018,TGTX,9.88,TG-1101 and TGR-1202 - UNITY-CLL study
Phase 3,1H 2018 ,06/30/2018,TNXP,3.80,TNX-102 SL
Phase 2/3,1H 2018 ,06/30/2018,TOCA,12.12,Toca 511 & Toca FC
Phase 2,1H 2018 ,06/30/2018,TPIV,3.61,TPIV200
Phase 1/2,1H 2018 ,06/30/2018,TSRO,69.59,Niraparib and Keytruda (TOPACIO)
Phase 1/2,1H 2018 ,06/30/2018,TTNP,1.38,Ropinirole implant
Phase 2,2Q 2018 ,06/30/2018,VICL,1.85,VCL-HB01 HSV-2 Therapeutic Vaccine
Phase 2,1H 2018 ,06/30/2018,VKTX,4.74,VK2809
Phase 2a,1H 2018 ,06/30/2018,VRNA,12.52,RPL554
Phase 2,1H 2018 ,06/30/2018,XLRN,45.12,ACE-083
Phase 3,2Q 2018 ,06/30/2018,ZGNX,37.60,ZX008 - Study 1504
PDUFA priority review,,07/06/2018,IONS,53.22,Inotersen (IONIS-TTRRx)
PDUFA,,07/28/2018,DRRX,1.17,RBP-7000
PDUFA,,07/28/2018,INSY,8.84,Buprenorphine
Phase 3,Mid-2018 ,07/31/2018,ALNY,129.07,Givosiran
Phase 3,Mid-2018 ,07/31/2018,ALXN,122.71,Eculizumab
Phase 2,Mid-2018 ,07/31/2018,BLRX,1.16,BL-8040
Phase 2/3,Mid-2018 ,07/31/2018,BYSI,25.74,Plinabulin (Trial 105)
Phase 2,Mid-2018 ,07/31/2018,CMTX,10.00,CX-072
Phase 3,Mid-2018 ,07/31/2018,EBIO,0.85,Vicinium
Phase 3,Mid-2018 ,07/31/2018,FOMX,6.70,FMX103
Phase 3,Mid-2018 ,07/31/2018,FOMX,6.70,FMX101 - FX2017-22
Phase 2,Mid-2018 ,07/31/2018,GNMX,1.30,AEVI-001 (NFC-1)
Phase 1/2,Mid-2018 ,07/31/2018,GNMX,1.30,AEVI-002 (Anti-LIGHT mAb)
Phase 1/2,2018 ,07/31/2018,JUNO,48.75,Lico-cel (CD-19 JCAR017) - TRANSCEND
Phase 3,Mid-2018 ,07/31/2018,LLY,86.98,Ramucirumab
Phase 2,Mid-2018 ,07/31/2018,MRTX,24.75,Sitravatinib plus nivolumab
Phase 2b,Mid-2018 ,07/31/2018,OBSV,9.70,OBE2109 - EDELWEISS
Phase 3,Mid-2018 ,07/31/2018,RDHL,5.17,RHB-104 MAP US
Phase 2b,Mid-2018 ,07/31/2018,SCYX,1.88,SCY-078 - oral
Phase 1/2,Mid-2018 ,07/31/2018,SNSS,4.25,SNS-062
Phase 2b,Mid-2018 ,07/31/2018,VRNA,12.52,RPL554
Phase 2,Mid-2018. ,07/31/2018,VTGN,1.26,AV-101
Phase 3,Mid-2018 ,07/31/2018,XLRN,45.12,Luspatercept - BELIEVE
Phase 3,Mid-2018 ,07/31/2018,XLRN,45.12,Luspatercept - MEDALIST
Phase 2,Mid-2018 ,07/31/2018,ZFGN,5.56,ZGN-1061
PDUFA,,08/11/2018,REGN,366.96,EYLEA
PDUFA,,08/26/2018,VRX,23.84,IDP-121
PDUFA,,08/30/2018,AKCA,17.00,Volanesorsen - APPROACH
Phase 1/2,3Q 2018 ,09/30/2018,AGLE,6.26,AEB1102
Phase 1/2,3Q 2018 est. ,09/30/2018,AGTC,4.20,rAAV-hRS1
–,3Q 2018 ,09/30/2018,AMRN,4.25,Vascepa REDUCE-IT outcomes trial
Phase 3,3Q 2018 ,09/30/2018,AQXP,11.51,AQX-1125 LEADERSHIP
Phase 3,3Q 2018 ,09/30/2018,CNCE,20.15,AVP-786
Phase 2,3Q 2018 ,09/30/2018,EIGR,16.00,Exendin 9-39
Phase 2,3Q 2018 ,09/30/2018,FLKS,4.20,FLX-787 - COMMEND US trial
Phase 3,3Q 2018 ,09/30/2018,GILD,79.02,F/TAF (Descovy)
Phase 3,3Q 2018 ,09/30/2018,HSGX,2.78,NeoCart
Phase 2,3Q 2018 ,09/30/2018,NVO,55.04,Concizumab - explorer
Phase 3,3Q 2018 ,09/30/2018,NVO,55.04,Somapacitan (NN8640) - REAL 3
Phase 3,3Q 2018 ,09/30/2018,PGNX,6.34,1404
Phase 2,3Q 2018 ,09/30/2018,RGLS,1.23,RG-012 - HERA
Phase 3,3Q 2018 ,09/30/2018,URGN,44.16,MitoGel - OLYMPUS
Phase 3,3Q 2018 ,09/30/2018,VTL,6.00,VTI-308
PDUFA,,10/10/2018,LLY,86.98,"Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN"
PDUFA,4Q 2018 ,10/19/2018,PRTK,17.85,Sarecycline
PDUFA,,10/23/2018,MRK,58.66,Doravirine (MK-1439)
PDUFA,,11/02/2018,TRVN,1.75,Oliceridine (TRV130)
Phase 3,2018 ,12/31/2018,ABBV,100.34,ABT-494 - SELECT-COMPARE
Phase 3,2018 ,12/31/2018,ABBV,100.34,Imbruvica - PHOENIX
Phase 2,2H 2018 ,12/31/2018,ABUS,5.10,"ARB-1467, tenofovir, and pegylated interferon"
Phase 1/2,2018 ,12/31/2018,ACIU,13.48,ACI-24 (anti-Abeta vaccine)
Phase 2,YE 2018 ,12/31/2018,ACRS,25.00,ATI-50002 - dose ranging
Phase 1/2,2H 2018 ,12/31/2018,ADVM,3.95,ADVM-043
Phase 2b,2018 ,12/31/2018,AGN,176.05,Brazikumab
Phase 3,2H 2018 ,12/31/2018,AGN,176.05,ABICIPAR
Phase 3,2H 2018 ,12/31/2018,AIMT,39.43,AR101 RAMSES
Phase 3,YE 2018 ,12/31/2018,AKBA,15.68,Vadadustat - TRILO2GY
Phase 2,YE 2018 ,12/31/2018,AKBA,15.68,Vadadustat - FO2RWARD
Phase 2,2018 ,12/31/2018,AKCA,17.00,AKCEA-ANGPTL3-LRx
Phase 2b,2018 ,12/31/2018,AKCA,17.00,AKCEA-APO(a)-LRx
Phase 2b,2H 2018 ,12/31/2018,ALDX,6.85,ADX-102
Phase 3,2H 2018 ,12/31/2018,ALDX,6.85,ADX-102
Phase 2,2H 2018 ,12/31/2018,ALDX,6.85,ADX-102
Phase 1/2,2018 ,12/31/2018,ALNY,129.07,ALN-CC5 (cemdisiran)
Phase 1/2,2Q 2018 ,12/31/2018,ALXN,122.71,ALXN1210
Phase 2,2H 2018 ,12/31/2018,ARGX,70.52,ARGX-113
Phase 2,2H 2018 ,12/31/2018,ARGX,70.52,ARGX-113
Phase 1/2,2H 2018 ,12/31/2018,AST,2.45,AST-VAC2
Phase 3,2018 ,12/31/2018,ATNX,15.87,Oraxol
Phase 2,2018 ,12/31/2018,ATOS,0.26,Endoxifen
Phase 2,2018 ,12/31/2018,ATOS,0.26,Endoxifen
Phase 2,2H 2018 ,12/31/2018,AUPH,5.35,Voclosporin
Phase 2,2H 2018 ,12/31/2018,AUPH,5.35,Voclosporin
Phase 3,2H 2018 ,12/31/2018,AZN,35.65,Farxiga - DECLARE
Phase 3,2H 2018 ,12/31/2018,AZN,35.65,Benralizumab - TERRANOVA
Phase 3,2H 2018 ,12/31/2018,AZN,35.65,Durvalumab +/- tremelimumab (NEPTUNE)
Phase 3,2H 2018 ,12/31/2018,AZN,35.65,Anifrolumab
Phase 2,2018 ,12/31/2018,BIIB,335.95,Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Phase 2,2H 2018 ,12/31/2018,BIIB,335.95,BAN2401 (Aβ mAb)
Phase 2b,YE 2018 ,12/31/2018,BLPH,2.03,INOpulse delivery device
Phase 2,YE 2018 ,12/31/2018,BLPH,2.03,INOpulse delivery device
Phase 3,2018 ,12/31/2018,BLPH,2.03,INOpulse delivery device
Phase 2b,2018 ,12/31/2018,BLRX,1.16,BL-8040
Phase 3,2H 2018 ,12/31/2018,BMY,62.81,CM-602 – Opdivo + Elo + SOC
Phase 3,2H 2018 ,12/31/2018,BMY,62.81,CM-459 – Opdivo
Phase 3,2H 2018 ,12/31/2018,BMY,62.81,CM-451 – Opdivo + Yervoy
Phase 3,2018 ,12/31/2018,BYSI,25.74,Plinabulin
Phase 2,2H 2018 ,12/31/2018,CANF,1.88,Namodenoson (CF102)
Phase 2,2018 ,12/31/2018,CASC,4.07,Tucatinib - MOUNTAINEER
Phase 3,2018 ,12/31/2018,CELG,106.00,OTEZLA - SPSO-001
Phase 3,2018 ,12/31/2018,CELG,106.00,REVLIMID - ROBUST
Phase 3,2018 ,12/31/2018,CELG,106.00,MM-007 OPTIMISMM
Phase 3,2018 ,12/31/2018,CELG,106.00,Oral Azacitidine - CC-486-AML-001
Phase 3,YE 2018 ,12/31/2018,CELG,106.00,ABRAXANE - PANC-003 apact
Phase 3,2018 ,12/31/2018,CELG,106.00,ABRAXANE - IMpower 130 ( I/O Combo)
Phase 3,2018 ,12/31/2018,CELG,106.00,ABRAXANE - IMpower 131 ( I/O Combo)
Phase 3,2018 ,12/31/2018,CELG,106.00,ABRAXANE - IMPassion ( I/O Combo)
Phase 2,4Q 2018 ,12/31/2018,CFRX,1.19,CF-301
Phase 2,2H 2018 ,12/31/2018,CMRX,4.92,IV Brincidofovir
Phase 2,2H 2018 ,12/31/2018,CMTX,10.00,CX-2009 - PROCLAIM
Phase 2,2H 2018 ,12/31/2018,CNAT,4.69,Emricasan
Phase 2a,2H 2018 ,12/31/2018,CNCE,20.15,CTP-543
Phase 3,4Q 2018 ,12/31/2018,EGRX,62.09,Fulvestrant
Phase 2,2H 2018 ,12/31/2018,EIGR,16.00,Ubenimex - ULTRA
Phase 2,2018 ,12/31/2018,EPZM,14.85,Tazemetostat
Phase 3,4Q 2018 ,12/31/2018,ESPR,73.26,Bempedoic Acid/ Ezetimibe (1002FDC-053)
Phase 3,2018 ,12/31/2018,FGEN,49.50,Roxadustat - ANDES
Phase 2,2018 ,12/31/2018,FLKS,4.20,FLX-787
Phase 2,2H 2018 ,12/31/2018,FLXN,26.45,Zilretta - SHIP
Phase 2,2H 2018 ,12/31/2018,GEMP,7.52,Gemcabene - AZURE-1
Phase 2,2H 2018 ,12/31/2018,GILD,79.02,Tirabrutinib (GS-4059)
Phase 2,2H 2018 ,12/31/2018,GILD,79.02,GS-9876
Phase 2,2H 2018 ,12/31/2018,GILD,79.02,GS-5734
Phase 2,2018 ,12/31/2018,GILD,79.02,Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
Phase 1/2,2018 ,12/31/2018,GILD,79.02,Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
Phase 1/2,2018 ,12/31/2018,GILD,79.02,Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
Phase 2,4Q 2018 ,12/31/2018,GTHX,23.04,Trilaciclib
Phase 2,YE 2018 ,12/31/2018,GTXI,11.81,Enobosarm
Phase 3,2H 2018 ,12/31/2018,GWPH,131.97,Epidiolex
Phase 3,2H 2018 ,12/31/2018,GWPH,131.97,Epidiolex
Phase 3,Late 4Q 2018 ,12/31/2018,HALO,20.36,PEGPH20 - HALO-301
Phase 1b,2018 ,12/31/2018,HALO,20.36,PEGPH20 in combination with KEYTRUDA
Phase 1b,2H 2018 ,12/31/2018,HTBX,0.43,HS-110 and nivolumab (Opdivo)
Phase 3,2018 ,12/31/2018,IMGN,7.79,Kadcyla (KATHERINE).
Phase 2,4Q 2018 ,12/31/2018,IMRN,7.45,IMM-124E
Phase 1/2,4Q 2018 ,12/31/2018,IMRN,7.45,IMM-529
Phase 2,YE 2018 ,12/31/2018,INSY,8.84,Cannabidiol
Phase 2,2018 ,12/31/2018,IOVA,9.00,LN-145
Phase 3,2018 ,12/31/2018,JNJ,145.76,STELARA (USTEKINUMAB)
Phase 1,2018 ,12/31/2018,JUNO,48.75,JCARH125
Phase 2b,2H 2018 ,12/31/2018,KPTI,10.78,Selinexor - SADAL
Phase 3,2018 ,12/31/2018,LLY,86.98,Flortaucipir F 18 (Tau imaging agent)
Phase 2,2H 2018 ,12/31/2018,MACK,10.74,MM-121 (SHERBOC)
Phase 2,2H 2018 ,12/31/2018,MACK,10.74,MM-121
Phase 1/2,2018 ,12/31/2018,MBRX,1.87,Annamycin
Phase 2,2018 ,12/31/2018,MRNS,7.34,Ganaxolone
Phase 2b,Late-2018 ,12/31/2018,NBIX,81.37,INGREZZA - T-Force GOLD
Phase 3,4Q 2018 or 1Q 2019 ,12/31/2018,NVAX,1.61,RSV vaccine - prepare trial
Phase 2,2018 ,12/31/2018,NVCR,21.70,Tumor Treating Fields (TTFields) STELLAR
Phase 3,2018 ,12/31/2018,NVS,86.65,QVM149
Phase 2a,YE 2018 ,12/31/2018,OBSV,9.70,OBE022 - PROLONG
Phase 3,2H 2018 ,12/31/2018,OCUL,5.60,OTX-TP
Phase 2b,2018 ,12/31/2018,ONCS,1.94,ImmunoPulse IL-12 - PISCES
Phase 2,2H 2018 ,12/31/2018,OVID,9.52,OV101 (STARS)
Phase 2a,2H 2018 ,12/31/2018,PIRS,7.46,PRS-080
Phase 1/2,2018 ,12/31/2018,PRQR,3.10,QR-010
Phase 2,Late 2018 ,12/31/2018,PULM,1.54,PUR1800
Phase 3,YE 2018 ,12/31/2018,QURE,17.59,AMT-061
Phase 1/2,2H 2018 ,12/31/2018,RARE,47.80,DTX301
Phase 3,2H 2018 ,12/31/2018,RDHL,5.17,RHB-105 - ERADICATE Hp 2
Phase 3,2018 ,12/31/2018,REGN,366.96,Dupixent (dupilumab)
Phase 3,2H 2018 ,12/31/2018,RETA,28.43,Bardoxolone methyl - CATALYST
Phase 1/2,Late 2018 ,12/31/2018,RGNX,30.45,RGX-501
Phase 2,2018 ,12/31/2018,RIGL,4.07,Fostamatinib
Phase 3,2H 2018 ,12/31/2018,RVNC,34.50,"RT002 - SAKURA 1, 2 and 3"
Phase 3,4Q 2018 ,12/31/2018,SBBP,8.00,COR-003 (levoketoconazole) - LOGICS
Phase 3,4Q 2018 ,12/31/2018,SCYX,1.88,SCY-078 - oral - CARES
Phase 3,4Q 2018 ,12/31/2018,SCYX,1.88,SCY-078 - oral (FURI)
Phase 3,2018 ,12/31/2018,SGEN,52.36,ADCETRIS in combination with chemotherapy - ECHELON-2
Phase 1/2,2018 ,12/31/2018,SGMO,18.30,SB-FIX
Phase 3,2H 2018 ,12/31/2018,SNNA,18.06,SNA-001
Phase 3,2H 2018 ,12/31/2018,SNNA,18.06,SNA-001
Phase 3,4Q 2018 ,12/31/2018,SNY,44.78,Isatuximab
Phase 3,YE 2018 ,12/31/2018,SVRA,13.05,Molgradex - IMPALA
Phase 3,2H 2018 ,12/31/2018,TBPH,26.98,Closed Triple - CAPTAIN
Phase 2,2018 ,12/31/2018,TCON,2.90,TRC105
Phase 2,2018 ,12/31/2018,TCON,2.90,TRC102
Phase 3,2H 2018 ,12/31/2018,TCON,2.90,TRC105 (TAPPAS)
Phase 1/2,2H 2018 ,12/31/2018,TSRO,69.59,Niraparib - AVANOVA
Phase 3,2018 ,12/31/2018,UTHR,141.27,Esuberaprost - BEAT
Phase 3,2H 2018 ,12/31/2018,UTHR,141.27,Orenitram
Phase 2,YE 2018 ,12/31/2018,VNDA,14.50,Tradipitant
Phase 3,2018 ,12/31/2018,VNDA,14.50,HETLIOZ (tasimelteon)
Phase 2,YE 2018 ,12/31/2018,XBIT,4.16,XBIO-101
Phase 2,4Q 2018 ,12/31/2018,XNCR,22.50,XmAb5871
Phase 3,Early 2019 ,03/31/2019,AIMT,39.43,AR101 ARTEMIS
Phase 3,1Q 2019 ,03/31/2019,ASND,46.58,TransCon
Phase 3,1Q 2019 ,03/31/2019,CLSD,6.35,Suprachoroidal CLS-TA - SAPPHIRE
Phase 3,1Q 2019 ,03/31/2019,CLSN,2.75,ThermoDox - OPTIMA
Phase 2b,1Q 2019 ,03/31/2019,GSK,37.50,Danirixin
Phase 2b,Early 2019 ,03/31/2019,ORMP,8.70,ORMD-0801
Phase 3,1Q 2019 ,03/31/2019,PRTO,2.50,Vonapanitase (PRT-201) PATENCY-2
Phase 2a,1Q 2019 ,03/31/2019,RNN,2.12,RX-3117 in combination with Abraxane
Phase 1,1H 2019 ,06/30/2019,ATRA,28.25,ATA188
Phase 3,1H 2019 ,06/30/2019,ATRA,28.25,ATA 129 - ALLELE
Phase 2,2H 2018 – 1H 2019 ,06/30/2019,BMY,62.81,CM-568 - Opdivo + Yervoy
–,1H 2019 ,06/30/2019,CMRX,4.92,Oral Brincidofovir
Phase 2,1H 2019 ,06/30/2019,CNAT,4.69,Emricasan
Phase 2,1H 2019 ,06/30/2019,FBIO,4.14,CEVA101
Phase 3,1H 2019 ,06/30/2019,GBT,56.60,GBT440 - HOPE
Phase 3,1H 2019 ,06/30/2019,GSK,37.50,Tapinarof (GSK2894512)
Phase 2b,1H 2019 ,06/30/2019,GSK,37.50,Inhaled PI3Kδ inhibitor
Phase 3,1H 2019 ,06/30/2019,ICPT,54.95,Ocaliva (Obeticholic acid (OCA)) - REGENERATE
Phase 1/2,1H 2019 ,06/30/2019,KMDA,5.65,Alpha-1 antitrypsin (AAT)
Phase 3,1H 2019 ,06/30/2019,NERV,6.25,MIN-101
Phase 2,1H 2019 ,06/30/2019,RARX,8.49,RA101495
Phase 3,1H 2019 ,06/30/2019,RYTM,27.40,Setmelanotide
Phase 1/2,1H 2019 ,06/30/2019,SNDX,9.19,Entinostat plus Tecentriq - ENCORE 603
Phase 2b,1H 2019 ,06/30/2019,SNNA,18.06,SNA-120
Phase 3,2018/19 ,06/30/2019,TBPH,26.98,Telavancin
Phase 2/3,1H 2019 ,06/30/2019,TGTX,9.88,TG-1101 and TGR-1202 - UNITY-NHL study
Phase 2,1H 2019 ,06/30/2019,VTGN,1.26,AV-101
Phase 3,Mid-late 2019 ,10/31/2019,ALNY,129.07,Fitusiran (ATLAS)
Phase 3,2019 ,12/31/2019,ABBV,100.34,Venetoclax
Phase 1/2,2019 ,12/31/2019,ADXS,2.96,Axalimogene filolisbac + durvalumab
Phase 2,2019 ,12/31/2019,AFMD,1.30,AFM13
Phase 3,2019 ,12/31/2019,AGN,176.05,RAPASTINEL
Phase 3,2019 ,12/31/2019,AKBA,15.68,Vadadustat - INNO2VATE
Phase 3,2019 ,12/31/2019,AKBA,15.68,Vadadustat - PRO2TECT
Phase 2,2019 ,12/31/2019,AKCA,17.00,AKCEA-ANGPTL3-LRx
Phase 2b,2019 ,12/31/2019,AKCA,17.00,AKCEA-APOCIII-LRx
Phase 3,2019 ,12/31/2019,AMGN,185.04,KYPROLIS (ARROW)
Phase 2b,2019 ,12/31/2019,ANAB,112.40,ANB020
Phase 3,2H 2019 ,12/31/2019,ATNM,0.74,Iomab-B
Phase 3,2019 ,12/31/2019,AZN,35.65,AZD3293
Phase 3,2019 ,12/31/2019,AZN,35.65,Durvalumab +/- tremelimumab (DANUBE)
Phase 3,2019 ,12/31/2019,AZN,35.65,Brilinta (THEMIS)
Phase 3,Late 2019 ,12/31/2019,BCLI,3.57,NurOwn
Phase 3,2H 2019 ,12/31/2019,BMRN,90.22,Vosoritide
Phase 3,2019 ,12/31/2019,BMY,62.81,CM-649 – Opdivo+ Yervoy or Chemo
Phase 3,2019 ,12/31/2019,BMY,62.81,CM-9LA Opdivo + Yervoy + Chemo
Phase 3,2019 ,12/31/2019,BMY,62.81,CM-651 – Opdivo + Yervoy
Phase 3,2019 ,12/31/2019,CELG,106.00,REVLIMID - MAGNIFY NHL-010
Phase 3,2019 ,12/31/2019,CHMA,1.48,Mycapssa - OPTIMAL
Phase 2b,2019 ,12/31/2019,CNAT,4.69,Emricasan
Phase 3,2019 ,12/31/2019,DCPH,24.54,DCC-2618 - INVICTUS
Phase 2,4Q 2019 ,12/31/2019,GALE,0.26,NeuVax in combination with Herceptin
Phase 3,2019 ,12/31/2019,GSK,37.50,Mepolizumab - SYNAPSE
Phase 3,2019 ,12/31/2019,IMGN,7.79,Kadcyla (KAITLIN)
Phase 2b,2019 ,12/31/2019,IMMP,1.90,Eftilagimod Alpha  - Active Immunotherapy PAClitaxel (AIPAC)
Phase 2,2019 ,12/31/2019,IMRN,7.45,IMM-124E
Phase 3,2019 ,12/31/2019,INCY,94.07,Ruxolitinib - REACH 3
Phase 3,2019 ,12/31/2019,JNJ,145.76,INVOKANA - CREDENCE
Phase 3,2019 ,12/31/2019,JNJ,145.76,DARZALEX (Daratumumab)
Phase 2,2H 2019 ,12/31/2019,KALV,10.01,KVD001
Phase 2/3,2019 ,12/31/2019,KPTI,10.78,Selinexor - SEAL
Phase 3,2019 ,12/31/2019,KPTI,10.78,Selinexor - BOSTON
Phase 3,YE 2019 ,12/31/2019,MDCO,27.51,Inclisiran
Phase 3,2019 ,12/31/2019,MRK,58.66,MK-8931 (019) - Verubecestat
Phase 3,2019 ,12/31/2019,NVS,86.65,QAW039 (fevipiprant)
Phase 3,2019 ,12/31/2019,NVS,86.65,OMB157 (ofatumumab)
Phase 3,2019 ,12/31/2019,NVS,86.65,Entresto - PARAGON
Phase 3,2019 ,12/31/2019,NVS,86.65,Entresto - PARADISE
Phase 3,2019 ,12/31/2019,NVS,86.65,AIN457 (Cosentyx)
Phase 3,2H 2019 ,12/31/2019,OBSV,9.70,OBE2109 - PRIMROSE 2
Phase 3,2H 2019 ,12/31/2019,OBSV,9.70,OBE2109 - PRIMROSE
Phase 2a,2H 2019 ,12/31/2019,OPHT,2.85,Zimura
Phase 1/2,2019 ,12/31/2019,OVAS,1.18,OvaPrime
Phase 3,2H 2019 ,12/31/2019,RETA,28.43,Bardoxolone methyl - CARDINAL
Phase 2,2H 2019 ,12/31/2019,RETA,28.43,Omaveloxolone - MOXIe
Phase 3,2H 2019 ,12/31/2019,VBIV,4.46,Sci-B-Vac - PROTECT
Phase 2/3,2019 ,12/31/2019,ZYNE,11.79,ZYN002
Phase 3,2020/21 ,06/30/2020,ADXS,2.96,Axalimogene filolisbac - AIM2CERV Trial
Phase 3,2020 ,12/31/2020,AGN,176.05,RELAMORELIN
Phase 3,2020 ,12/31/2020,AZN,35.65,Durvalumab (ADJUVANT)
Phase 3,2020 ,12/31/2020,BLRX,1.16,BL-8040 GENESIS
Phase 3,2020 ,12/31/2020,CATB,1.54,Edasalonexent (CAT-1004)
Phase 3,2020 ,12/31/2020,CELG,106.00,REVLIMID - MAGNIFY NHL-008
Phase 3,2020 ,12/31/2020,CHMA,1.48,Mycapssa - MPOWERED
Phase 3,2020 ,12/31/2020,CRBP,8.20,Anabasum (Resunab)
Phase 3,2020 ,12/31/2020,GSK,37.50,Daprodustat - ASCEND-D
Phase 3,2020 ,12/31/2020,INCY,94.07,Ruxolitinib - REACH 2
Phase 2,2020 ,12/31/2020,KZIA,2.88,GDC-0084
Phase 3,2020 ,12/31/2020,NVCR,21.70,Tumor Treating Fields (TTFields) METIS
Phase 2b,2020 ,12/31/2020,OPHT,2.85,Zimura
Phase 3,2020 ,12/31/2020,PRTA,41.33,NEOD001 VITAL
Phase 3,2021 ,12/31/2021,NVCR,21.70,Tumor Treating Fields (TTFields) LUNAR
Phase 2/3,2023 ,12/31/2023,NVS,86.65,CNP 520
